These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 20123556)
21. Treatment of motor dysfunction in Parkinson's disease: an overview. Thobois S; Delamarre-Damier F; Derkinderen P Clin Neurol Neurosurg; 2005 Jun; 107(4):269-81. PubMed ID: 15885384 [TBL] [Abstract][Full Text] [Related]
22. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Falk T; Zhang S; Sherman SJ Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875 [TBL] [Abstract][Full Text] [Related]
23. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease. Liu WG; Lu GQ; Li B; Chen SD Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309 [TBL] [Abstract][Full Text] [Related]
24. Where do we stand on neuroprotection? Where do we go from here? Shoulson I Mov Disord; 1998; 13 Suppl 1():46-8. PubMed ID: 9613718 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
26. Heredity in Parkinson's disease: new findings. Lev N; Melamed E Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638 [TBL] [Abstract][Full Text] [Related]
27. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Schapira AH Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314 [TBL] [Abstract][Full Text] [Related]
28. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? Vale S Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172 [TBL] [Abstract][Full Text] [Related]
29. Parkinson's at risk syndrome: can Parkinson's disease be predicted? Stern MB; Siderowf A Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248 [TBL] [Abstract][Full Text] [Related]
30. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Marek K; Jennings D; Tamagnan G; Seibyl J Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587 [TBL] [Abstract][Full Text] [Related]
31. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Lindvall O; Wahlberg LU Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752 [TBL] [Abstract][Full Text] [Related]
32. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Stocchi F; Olanow CW Mov Disord; 2013 Jan; 28(1):3-7. PubMed ID: 23390094 [TBL] [Abstract][Full Text] [Related]
33. Advances in the genetics of Parkinson's disease. Rosner S; Giladi N; Orr-Urtreger A Acta Pharmacol Sin; 2008 Jan; 29(1):21-34. PubMed ID: 18158863 [TBL] [Abstract][Full Text] [Related]
34. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Youdim MB; Geldenhuys WJ; Van der Schyf CJ Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251 [TBL] [Abstract][Full Text] [Related]
35. The clinical progression of Parkinson's disease. Poewe W; Mahlknecht P Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S28-32. PubMed ID: 20123553 [TBL] [Abstract][Full Text] [Related]
36. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Silva RM; Kuan CY; Rakic P; Burke RE Mov Disord; 2005 Jun; 20(6):653-64. PubMed ID: 15719422 [TBL] [Abstract][Full Text] [Related]
37. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565 [TBL] [Abstract][Full Text] [Related]